Clinical Trial Update: Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial investigated the JAK1/2 inhibitor baricitinib for chronic graft-versus-host disease following allogeneic hematopoietic stem cell transp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-10-25